Fireside Project is excited to launch on April 14th as a 24/7 support hotline for people who are currently struggling through a psychedelic experience; are supporting others who are having a difficult experience; or who need to process & integrate past psychedelic experiences. Please add 6-2-Fireside (623-473-7433) into your phone, and share this number with those who could also benefit.
Similar Posts
How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more
How long until Psychedelic Stocks Payoff?🍄🚀
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.
And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.
In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”
Or, translated to Reddit-speak: when moon?
To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.
There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.
The first will happen relatively soon.
#PsychedelicStocks #MindMed #Cybin
Interview With Daniel Carcillo
In this episode of the Psychedelic Spotlight podcast we catch up with Daniel Carcillo, Founder and CEO of Wesana Health.
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
Interview With Douglas K. Gordon
CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
Transforming Your Life After 50 Through Microdosing with Cesar Marin
In this episode, we dive into the transformational testimonial of Cesar Maren’s experience with microdosing. Once a CNN TV producer, and now a full time advocate for the power of intentional microdosing, Cesar shares with us his journey how it helped transform his life.
SPOTLIGHT IN FOCUS – The Rise of Psychedelic Therapy
Dr. Zinia Thomas at Radiance Wellness, St. Louis MO –…